EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis

Jens Ingvarsson iD, Viktor Grut iD, Martin Biström iD, Linn Persson Berg, Pernilla Stridh, Jesse Huang, Jan Hillert, Lars Alfredsson, Ingrid Kockum, Tomas Olsson, Tim Waterboer, Staffan Nilsson und 1 weitere

European Journal of Neurology · 2024

DOI: 10.1111/ene.16387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Jens Ingvarsson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden. Hauptthemen laut MEDLINE: Multiple Sclerosis, Rubella virus, Rubella. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Neuro foundation, Forskningsrådet om Hälsa, Arbetsliv och Välfärd, Hjärnfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multiple sclerosis (MS) is a demyelinating disease affecting millions of people worldwide. Hereditary susceptibility and environmental factors contribute to disease risk. Infection with Epstein–Barr virus (EBV) and human herpesvirus 6A (HHV‐6A) have previously been associated with MS risk. Other neurotropic viruses, such as rubella virus (RV), are possible candidates in MS aetiopathogenesis, but previous results are limited and conflicting.

Methods

In this nested case–control study of biobank samples in a Swedish cohort, we analysed the serological response towards RV before the clinical onset of MS with a bead‐based multiplex assay in subjects vaccinated and unvaccinated towards RV. The association between RV seropositivity and MS risk was analysed with conditional logistic regression.

Results

Seropositivity towards RV was associated with an increased risk of MS for unvaccinated subjects, even when adjusting for plausible confounders including EBV, HHV‐6A, cytomegalovirus and vitamin D (adjusted odds ratio [AOR] = 4.0, 95% confidence interval [CI] 1.8–8.8). Cases also had stronger antibody reactivity towards rubella than controls, which was not seen for other neurotropic viruses such as herpes simplex or varicella zoster. Furthermore, we observed an association between RV seropositivity and MS in vaccinated subjects. However, this association was not significant when adjusting for the aforementioned confounders (AOR = 1.7, 95% CI 1.0–2.9).

Conclusions

To our knowledge, these are the first reported associations between early RV seropositivity and later MS development. This suggests a broadening of the virus hypothesis in MS aetiology, where molecular mimicry between rubella epitopes and human central nervous system molecules could be an attractive possible mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisRubella virusRubellaHumansMaleFemaleCase-Control StudiesMiddle AgedAdultRisk FactorsAntibodies, ViralVaccinationSwedenRubella VaccineCohort StudiesHerpesvirus 6, HumanAged

Substanzen

Antibodies, ViralRubella Vaccine

Autor:innen und Institutionen

  • Department of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.
  • Department of Infectious Diseases, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
  • Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Jens Ingvarsson, Viktor Grut, Martin Biström

Förderung

  • the Neuro foundation
  • Forskningsrådet om Hälsa, Arbetsliv och Välfärd
  • Hjärnfonden
  • Margaretha af Ugglas foundation
  • Horizon 2020 MultipleMS
  • Oskarfonden
  • NEURO Sweden
  • Vetenskapsrådet

Zitieren

APA

Ingvarsson, J., Grut, V., Biström, M., Berg, L. P., Stridh, P., Huang, J., Hillert, J., Alfredsson, L., Kockum, I., Olsson, T., Waterboer, T., Nilsson, S., & Sundström, P. (2024). Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.16387

Vancouver

Ingvarsson J, Grut V, Biström M, Berg LP, Stridh P, Huang J, et al. Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis. European Journal of Neurology. 2024. doi:10.1111/ene.16387

BibTeX
@article{Ingvarsson2024,
  author = {Ingvarsson, Jens and Grut, Viktor and Biström, Martin and Berg, Linn Persson and Stridh, Pernilla and Huang, Jesse and Hillert, Jan and Alfredsson, Lars and Kockum, Ingrid and Olsson, Tomas and Waterboer, Tim and Nilsson, Staffan and Sundström, Peter},
  title = {Rubella virus seropositivity after infection or vaccination as a risk factor for multiple sclerosis},
  journal = {European Journal of Neurology},
  year = {2024},
  doi = {10.1111/ene.16387}
}
Kostenlos starten →